Hi Goffy,
I don’t have personal experience of this as a patient but my reading up says that this is doable. However, it may not be necessary, at least for a while.
Some background (a bit simplified, partly because I am merely a simple patient 😀). Immunotherapy works by attaching to something which is generally part of a myeloma cell but generally not part of a healthy cell. It then gets the immune system to attack and destroy the attached cell.
There are 3 parts of the myeloma cell that many different treatments currently use.
CD38: Daratumumab and Isatuximab
BCMA: Belantamab, Elranatamab, Teclistamab
GPRC5D: Talquetamab.
If you have been using an immunotherapy such as Daratumumab, the myeloma cells can ‘evolve’ into having less or none of that part (in this case, CD38). That would make Dara and Isatuximab less effective or ineffective.
However, after some time on a different type of immunotherapy (such as Belantamab) the previous myeloma cell part can sometimes return, making the treatment effective again.
However, as you can see, there are plenty of alternatives, since there are a number of treatments that aren’t even immunotherapy.
Sorry for the long and complicated answer.
Regards
Rabbit
-
This reply was modified 6 hours, 22 minutes ago by
rabbit.